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ABSTRACT
Objective To describe the rational for, and the methods 
that will be employed to develop, the WHO package of eye 
care interventions (PECI).
Methods and analysis The development of the 
package will be conducted in four steps: (1) selection of 
eye conditions (for which interventions will be included 
in the package) based on epidemiological data on the 
causes of vision impairment and blindness, prevalence 
estimates of eye conditions and health facility data; (2) 
identification of interventions and related evidence for the 
selected eye conditions from clinical practice guidelines 
and high- quality systematic reviews by a technical 
working group; (3) expert agreement on the inclusion of 
eye care interventions in the package and the description 
of resources required for the provision of the selected 
interventions; and (4) peer review. The project will be 
led by the WHO Vision Programme in collaboration with 
Cochrane Eyes and Vision. A Technical Advisory Group, 
comprised of public health and clinical experts in the 
field, will provide technical input throughout all stages of 
development.
Results After considering the feedback of Technical 
Advisory Group members and reviewing- related evidence, 
a final list of eye conditions for which interventions will be 
included in the package has been collated.
Conclusion The PECI will support Ministries of Health in 
prioritising, planning, budgeting and integrating eye care 
interventions into health systems. It is anticipated that the 
PECI will be available for use in 2021.
INTRODUCTION
Achieving Universal Health Coverage (UHC) 
is a WHO strategic priority. The objective 
of UHC is to ensure that all people have 
access to the promotive, preventive, curative 
and rehabilitative services they need, when 
and where they need them, without being 
exposed to financial hardship.1 In October 
2019, the WHO launched the first World 
Report on Vision to emphasise the urgent 
need for improved eye care globally, high-
lighting the role of eye care in contributing to 
UHC, and call for coordinated and concerted 
global action towards strengthening eye care 
in health systems.2
While many eye care interventions 
are cost- effective and feasible to imple-
ment,3 4 persistent inequities in access to 
eye care services exist2. The gap between 
existing eye care needs and access to services 
is greater in low- income and middle- income 
countries and underserved populations, such 
as people living in rural areas, those with 
low incomes, women, older people, people 
with certain kinds of disability, indigenous 
populations and ethnic minorities2. Several 
factors accentuate the challenges associated 
with the delivery of equitable services. Major 
Key messages
What is already known about this subject?
 ► Eye care medicines and interventions are not inte-
grated into the health insurance schemes in many 
low- income and middle- income countries.
What are the new findings?
 ► The package of eye care interventions will support 
countries to determine the (1) eye care interventions 
to prioritise, (2) workforce competencies, equipment, 
medicines, consumables and assistive technologies 
necessary for the implementation of eye care inter-
ventions and (3) costs associated with the imple-
mentation of evidence- based eye care interventions.
How might these results change the focus of 
research or clinical practice?
 ► It is the intention that the package of eye care inter-
ventions will take an important step to strengthening 
eye care within health systems, enabling more peo-
ple to benefit from eye care interventions.
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demographic trends, including population ageing and 
lifestyle factors, will cause a substantial increase in the 
number of people with eye conditions5–7 and, thus, have 
a profound impact on the already strained health system 
and eye care workforce.
The costs associated with accessing eye care services pose 
a major barrier to addressing the inequities in access to, 
and provision of, eye care services across the population. 
Therefore, an important component of UHC for eye care 
is that all people obtain the eye care services they need 
without risking financial hardship from unaffordable 
out- of- pocket payments. In order for countries to move 
towards UHC including eye care, they need to advance 
in three dimensions (figure 1)1 . First, priority eye care 
interventions and services included within health benefit 
packages need to be expanded; second, a greater propor-
tion of the population needs to be covered; and third, 
out- of- pocket payments need to be reduced. Countries 
are required to make important choices when addressing 
these dimensions, such as which interventions and popu-
lation groups should be prioritised.
To facilitate the choices that countries make when 
advancing UHC through eye care, WHO will develop 
a package of evidence- based eye care interventions to 
assist countries in making decisions on which interven-
tions to prioritise, how these can be budgeted, and then 
integrated into national health services packages and 
policies. The objective of this paper is to describe the 
methods that will be employed to develop the package of 
eye care interventions (PECI).
MATERIALS AND METHODS
The development of the PECI will follow a stepwise 
approach with the involvement of different stakeholders 
(figure 2). WHO Vision Programme (WHO VP) will be 
responsible for the overall coordination of the project as 
well as technical and development work. Cochrane Eyes 
and Vision (CEV) will be an official partner in developing 
the PECI and will provide methods and evidence exper-
tise. A WHO steering committee will oversee the project 
Figure 1 Dimensions of UHC.1 UHC, Universal Health 
Coverage.
Figure 2 Phases of the development of the PECI, the groups responsible for each phase and an overview of the timeline for 
development (adapted from: The World Report on Vision2). CEV, Cochrane Eyes and Vision; DG, Development Group; PECI, 
package of eye care interventions; PRG, Peer Review Group; TAG, Technical Advisory Group; TWG, Technical Working Group; 
WHO VP, WHO Vision Programme.
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and a Technical Advisory Group (TAG), comprised of 
public health, methods experts and clinical leaders in the 
field of eye care from all six WHO regions, will provide 
technical input throughout the different stages of devel-
opment. Eye care experts will also collaborate with WHO 
in the identification of evidence on eye care interven-
tions and creating descriptions of resources required for 
the provision of each intervention.
The declaration of interests of all external contribu-
tors will be assessed by an ethics officer from the Office 
of Compliance, Risk Management and Ethics at WHO. 
In the event that a conflict of interest (COI) exists, the 
ethics officer will advise on which COIs can be managed 
and which preclude participation.
Phase 1. Selection of eye conditions
The initial step of the development process involved the 
selection of eye conditions for which interventions will be 
included in the PECI. An initial selection performed by 
staff members from the WHO VP after considering the 
following evidence: (1) articles published in the scientific 
literature after 2010 reporting eye care facility data; (2) 
frequency data on the reasons for clinic attendance, over 
a predefined period, from selected health facilities located 
in a range of world regions and different resource settings; 
(3) global and/or regional population- based data on the 
causes of vision impairment and blindness among adult 
populations; (4) epidemiological data on the causes of 
childhood vision impairment and blindness; and (5) global 
and/or regional prevalence estimates of eye conditions.
TAG members were requested to independently review 
and provide written feedback on the collated data and 
preselected list of eye conditions, which was further 
discussed at the first TAG consultation of the PECI held 
on 25 March 2020.
Phase 2. Identification of evidence on eye care interventions
The identification of evidence on eye care interventions 
for each of the selected eye conditions will be performed 
by a Technical Working Group (TWG) made up of 
researchers from the field, including staff members from 
the WHO VP as well as members of external academic 
institutes.
Clinical Practice Guidelines (CPGs) will form the 
primary source of evidence for identifying relevant 
interventions to include in the PECI as they cover the 
continuum of care for a given eye condition by combining 
existing scientific evidence along with clinical expertise. 
Furthermore, CPGs cover the evidence gaps of the litera-
ture through expert consensus procedures. High- quality 
systematic reviews, such as Cochrane Systematic Reviews, 
will also be used to complement the evidence of CPGs 
when applicable (see Identification of systematic reviews 
section).
Identification of CPGs
The identification and selection of the CPGs will follow 
a stepwise approach (figure 3). An information specialist 
from CEV will design and carry out a single, system-
atic literature search of selected academic (MEDLINE, 
Embase, CINAHL, Global Health, Global Index 
Medicus) and guideline databases (online supplementary 
appendix 1). MeSH terms will be used where applicable. 
In addition, professional ophthalmology and optometry 
associations’ websites will be searched for relevant guide-
lines (online supplementary appendix 1). The search 
terms and filters will be adapted according to the search 
options in the specific guideline databases and websites. 
All the searches will be limited to the last 10 years and to 
English language.
Two members of the TWG independently will screen 
the titles and abstracts of articles identified from the 
systematic literature searches. Abstrackr, a semiauto-
mated online citation screening program, will be utilised 
where possible8 . The following exclusion criteria will be 
Figure 3 Flowchart for the identification of CPGs. 
CEV, Cochrane Eyes and Vision; CPGs, Clinical Practice 
Guidelines; TWG, Technical Working Group; WHO VP, WHO 
Vision Programme.
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applied: (1) the identified literature is not a guideline 
(ie, CPG or preferred practice pattern guideline); (2) 
the guideline is not related to the selected eye condi-
tions; (3) the guideline is older than 10 years; and (4) 
the guideline is not in English. All disagreements will be 
resolved by discussion between a CEV representative and 
the WHO.
For each selected eye condition, two members of the 
TWG will independently conduct full- text screening 
of the guidelines identified as possibly relevant for the 
selected eye condition, adopting the following exclusion 
criteria: (1) presence of commercial funding and/or 
unmanaged conflicts of interest of contributors; and (2) 
absence of affiliations of all contributors. Disagreements 
will be resolved by discussion.
The quality of CPGs included after full- text screening 
will be evaluated by the same two members of the TWG 
using the ‘Appraisal of Guidelines for Research and Eval-
uation’ (AGREE II) tool9 working independently. Nine 
items (4, 7, 8, 10, 12, 13, 15, 22 and 23) will be specif-
ically used for the selection of guidelines. These items 
are the same as those utilised in the development of 
the package of rehabilitation interventions and were 
selected based on a consensus finding process among 
three researchers.10 If the rating of an item differs by 
more than two points between the two researchers, the 
results will be discussed between the two TWG members 
(and a representative of WHO or CEV if necessary) to 
reach consensus. If consensus cannot be reached, a third 
member of the TWG will be consulted. Following evalua-
tion with the AGREE II tool, guidelines will be excluded 
if (1) the average score of the two researchers for items 4, 
7, 8, 12, or 22 is below 3; and (2) the sum of the average 
score of the two researchers for all nine items is <45.
A maximum of five CPGs will be selected per eye condi-
tion. In the case that specific guidelines for children, 
youth and adults are available for a given eye condition, 
up to five CPGs will be included for each age group. 
Where more than five guidelines are identified for a 
given eye condition, the selection of CPGs will be made 
via consensus procedures among members of the WHO 
VP and CEV (with or without input from individual TAG 
members) after considering relevant information (eg, 
AGREE II score, date of publication, representativeness 
of the CPG (ie, country, regional, international scope)).
Identification of systematic reviews
Systematic reviews will be used to complement the 
evidence of CPGs when (1) no CPGs are identified for 
a given eye condition following screening and quality 
appraisal; (2) the selected high- quality CPGs provide 
contradictory recommendations for a given interven-
tion; and/or (3) the CPG makes a recommendation on 
a given intervention based on evidence that is older than 
10 years.
CEV will identify all Cochrane systematic reviews in 
the Cochrane library, published or updated in the last 
10 years, either managed by CEV or with eyes and vision 
as a topic. Two members of the TWG will independently 
perform title and abstract screening. Systematic reviews 
will be excluded if they are not an intervention or diag-
nostic test accuracy review that is specifically related 
to the target eye condition. All disagreements will be 
resolved via discussion among TWG members with or 
without input from WHO and CEV representatives.
CEV US satellite maintains a database of other (ie, 
non- Cochrane) high- quality systematic reviews in eyes 
and vision11 . Systematic reviews published in English 
within the last 10 years using the same exclusion criteria 
as that of Cochrane systematic reviews will be identi-
fied. In addition, to ensure only high- quality systematic 
reviews are selected, the two TWG members will inde-
pendently appraise the quality of the methodology of 
each identified systematic review using the ‘A MeaSure-
ment Tool to Assess Systematic Reviews’ 2 (AMSTAR 2) 
tool. The AMSTAR 2 expert group set out seven domain 
items (ie, items 2, 4, 7, 9, 11, 13 and 15) that may criti-
cally affect the validity of a review and its conclusions.12 
A two- stage process will be followed: (1) reviews will be 
screened on item 2 (ie, whether the report of the review 
contained an explicit statement that the review methods 
were established prior to the conduct of the review); 
and (2) AMSTAR 2 assessment of the remaining critical 
domains will only be completed on reviews for which 
item 2 was rated as ‘yes’. Disagreements will be resolved 
by discussion between the TWG members and CEV 
representative. Systematic reviews will only be selected if, 
following an adjudication process (where applicable), all 
of the remaining critical domain items (4, 7, 9, 11, 13 and 
15) are rated as ‘yes’ or ‘partial yes’ by both researchers.
Data extraction and preparation
Data extraction will be completed by one member of 
the TWG and checked by another. Data extraction from 
CPGs will include information on the following domains: 
(1) information on the guideline (ie, title, authors, year 
of publication); (2) reference to the recommendations, 
interventions and related outcomes; (3) content and 
strength of the recommendation/s; and (4) quality of 
evidence related to the recommendation/s. For system-
atic reviews, information on the population, intervention 
and control, setting, statistical values for each of the 
analysis, number of studies and sample characteristics, 
summary of main results, certainty of evidence and 
adverse events will be extracted.
Phase 3. Approval of evidence-based eye care interventions 
and description of resources required for their provision
Specific Development Groups (DGs) will be founded 
for each eye care subspecialty areas (eg, retina, anterior 
segment, glaucoma, paediatric, etc) and will include clin-
ical, academic and public health professionals from all 
WHO regions (with a focus on low- income and middle- 
income countries), with working or research experience 
in the provision of interventions along the life course 
(paediatric and adult care).
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A three- step process will be carried out among each 
subspecialty- specific DG in order to (1) achieve consensus 
on the inclusion of evidence- based eye care interven-
tions in the PECI for each eye condition; (2) identify any 
relevant interventions that were not included within the 
list formulated by the TWG to be considered for inclu-
sion within the PECI (if applicable); and (3) agree on 
the service delivery platforms, workforce competencies 
and time and resources required to provide each of the 
selected interventions. This will consist of an initial online 
survey among each DG member, followed by data prepa-
ration by WHO (with or without input from specific DG 
members) and a web- based group discussion/s among 
DG members.
Online preparatory survey
Prior to undertaking the online survey, each DG member 
will receive the extracted information that was generated 
by the TWG, including full texts of the selected CPGs and 
the data extracted from the CPGs and systematic reviews 
(where applicable). For each given intervention, the 
DG members will be required to confirm whether they 
recommend the intervention for inclusion in the PECI 
based on the strength and quality of the recommenda-
tions, as well as its applicability and appropriateness in 
their own settings. If the intervention is recommended 
for inclusion in the PECI, the DG member will then (1) 
assign each intervention to one or more service delivery 
platforms (eg, school, outreach, hospital (in- patient 
or outpatient), clinic, home); and (2) identify missing 
interventions that were not identified by the TWG but 
are considered by the DG member as relevant to the eye 
condition.
Data preparation
Following the completion of the online survey by all 
members of the subspecialty DG, the WHO VP will 
collate a list of interventions in which majority agreement 
was achieved during the online survey and a separate list 
of interventions that did not achieve majority consensus, 
and thus require further deliberation. In addition, 
systematic literature searches will be coordinated with 
CEV for any missing interventions that were identified by 
the DG. Whenever the evidence supports the suggested 
assessment or intervention, it will be added to the list of 
interventions that requires further deliberation during 
the web- based group discussion.
For each of the interventions that achieved majority 
consensus during the online survey, WHO will be respon-
sible for drafting descriptions of the required resources 
and other relevant information for the intervention 
including the (1) target population (stage of life course, 
special context target population); (2) workforce require-
ment; (3) most appropriate service delivery platform/s 
(based on the survey results); (4) time required to provide 
each activity/procedure related to the intervention (per 
unit/event); and (5) required health products including 
equipment, consumables and assistive products.
Web-based group discussions
The DG results from the online survey, coupled with 
additional data collated by WHO in the data prepara-
tion stage, will be presented to DG members prior to a 
web- based group discussions. The objectives of the initial 
group discussions are twofold. First, to confirm the list 
of interventions to be included in the package. This will 
involve achieving consensus on (1) interventions that 
did not achieve majority agreement for inclusion in the 
package during the online survey and (2) identified 
missing interventions after considering the evidence 
derived from the systematic literature searches. Second, 
to review and update (if applicable) data collated by 
WHO on the service delivery platforms, equipment and 
workforce requirements for interventions that achieved 
consensus during the online survey. Following this, WHO 
will collate data relating to service delivery platforms, 
equipment and workforce requirements for interventions 
identified in (1) and (2) above that achieved majority 
agreement for inclusion in the PECI and follow- up web- 
based group discussion/s will be held to review and 
update this information.
Prior to peer review and to avoid overlap in the provi-
sion of resources, discussions will be held between WHO 
and selected members from each DG to identify cross- 
cutting interventions that for a multitude of reasons, 
including complementary workforce competencies 
and health product requirements, are relevant to the 
diagnosis, management or treatment of multiple eye 
conditions.
Phase 4. Peer review
A Peer Review Group (PRG) comprised of internal 
(WHO) members and eye care experts from all WHO 
regions will be formed. PRG members will be respon-
sible for independently reviewing the package and 
providing feedback and recommendations for revision. 
The presented package will include a list of interventions 
with core data. All feedback and recommendations will 
be considered before producing the first version of the 
PECI.
The patient and public involvement
It was not deemed appropriate for patients and/or the 
public to be involved in the design, conduct, reporting or 
dissemination of this work.
RESULTS
Selection of eye conditions for inclusion in the PECI
After considering the feedback of TAG members and 
reviewing related evidence, a final list of eye conditions 
for inclusion in the PECI was collated (box 1).
DISCUSSION
This paper presents the methodology for the devel-
opment of the WHO evidence- based PECI. In brief, 
the PECI will support countries to determine the (1) 
eye care interventions to prioritise, (2) workforce 
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competencies, equipment, medicines, consumables 
and assistive technologies necessary for the imple-
mentation of eye care interventions and (3) costs 
associated with the implementation of evidence- based 
eye care interventions. It is anticipated that the PECI 
will be available for use in 2021.
Eye care medicines and interventions are not inte-
grated into the health insurance schemes in many 
low- income and middle- income countries4 . An 
important component of UHC for eye care is that all 
people obtain the eye care services they need without 
risking financial hardship from unaffordable out- of- 
pocket payments. Thus, in order to promote equitable 
access to services, including protection against 
financial hardship, a shift is required to ensure that 
high- priority eye care interventions are included in 
service packages covered by prepaid pooled financing. 
This is particularly important for the poor. Once final-
ised, the PECI will be integrated in the WHO’s UHC 
compendium of interventions, containing interven-
tions across all of WHO’s programmatic health areas, 
and linked with the WHO OneHealth Tool, a single 
framework for planning, costing, impact analysis, 
budgeting and financing. When considered together 
with reliable data about the population eye care 
needs, these resources will facilitate discussions in low- 
income and middle- income countries around what eye 
care services to provide within their national health 
services packages.
While the primary audience for the PECI will be 
Ministries of Health (MoH) and other ministries 
involved in eye care service delivery in low- income 
and middle- income settings, there are a number of 
other potential end- users of the PECI. Government 
service providers will be able to use the PECI to plan 
and implement specific eye care interventions in their 
service programmes. Training facilities can use the 
PECI to develop their curricula for the training of 
health workers involved in eye care. In addition, based 
on the results of stage 2 of the development process—
the systematic identification and quality appraisal 
of CPGs and systematic reviews—researchers will be 
able to identify current gaps in evidence and define 
research strategies to address these gaps.
The scope of eye conditions included in the PECI 
goes beyond the leading causes of vision impairment 
and blindness. The inclusion of eye conditions that 
may not typically cause vision impairment, such as dry 
eye disease, conjunctivitis, pterygium and blepharitis, 
is important for several reasons. First, these condi-
tions are troublesome and painful and often severely 
impact on quality of life.13–15 Second, these condi-
tions are frequently among the leading reasons for 
presentation to eye care services in all countries and 
thus expose individuals to financial burden.16–20 The 
list of eye conditions included in the priority PECI is 
not meant to be exhaustive or exclusive, but rather 
represent a selection of conditions and eye care inter-
ventions that are supported by high- quality evidence 
and that are applicable to most low and intermediate 
resource settings. Future work will involve refining 
and expanding the PECI, drawing on newly available 
evidence and newly collected data on service provi-
sion. It is important to note that intervention packages 
for vision rehabilitation, trachoma, onchocerciasis, 
vitamin A deficiency, measles and rubella were not 
considered in the PECI as they are encompassed under 
the WHO Department of Neglected Tropical Diseases 
and WHO’s Programmes on Nutrition and Reha-
bilitation, respectively. Once finalised, the selected 
interventions will undergo a process of prioritisation, 
with input from clinical and public health specialists 
from all WHO regions, in order to develop recommen-
dations for a ‘basic’ package of interventions to assist 
countries when making choices of which interventions 
to prioritise in their service packages.
Some potential limitations should be considered 
regarding the methodology employed for the devel-
opment of the PECI. First, the utilisation of CPGs as 
the primary source of evidence for the selection of 
Box 1 Selection of eye conditions for inclusion in the 
PECI (not in order of priority)
1. Cataract
2. Congenital cataract
3. Refractive error
4. Diabetic retinopathy
5. Glaucoma
6. Congenital glaucoma
7. Age- related macular degeneration
8. Myopic macular degeneration
9. Amblyopia
10. Strabismus
11. Retinopathy of prematurity
12. Uveitis
13. Ocular trauma1
14. Ocular surface disorders2
a. Conjunctivitis (infective and allergic)
b. Dry eye disease
c. Keratoconus
d. Keratitis and corneal ulcer
e. Pterygium
15. Disorders of the eyelid and lacrimal system2
a. Ptosis, entropion and ectropion
b. Congenital anomalies
c. Blepharitis
d. Chalazion and hordeolum
1Interventions for the treatment of corneal opacities due to ‘ocular 
trauma’ and complications of ‘ocular surface disorders’ to be included.
2Key conditions have been defined under the broader categories of 
‘ocular surface disorders’ and ‘disorders of the eyelid and lacrimal 
system’ in recognition of the different treatment approaches required 
and to facilitate the identification of evidence on interventions for each 
condition. Eye conditions 1–13 will be all inclusive in terms of their 
coverage of interventions for the variety of subclassifications.
PECI, package of eye care interventions.
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interventions may be viewed as controversial given 
that the vast majority of scientific evidence forming 
the basis of the CPGs often originates from high- 
income settings, and therefore may not be pertinent 
to low resource settings. To address this, eye care 
experts from low- income and middle- income settings 
will be involved in all stages of development of the 
package, including during the process of defining the 
workforce competencies and resource requirements 
for the delivery of interventions. Second, limiting the 
search of CPGs and systematic reviews to the English 
language (only) will result in relevant CPGs published 
in other languages being overlooked. This deci-
sion was one of feasibility given the labour- intensive 
nature of screening CPGs published in all official 
WHO languages and later translation of the extracted 
information. In instances where there is an absence 
of evidence, WHO representatives will consult specific 
TAG members to determine benefit and feasibility of 
identifying evidence from CPGs published in other 
languages. Lastly, using the eye condition as a starting 
point for the PECI development may be perceived 
as counterintuitive for the integration of eye care 
interventions within the broader health system. As 
mentioned previously, the PECI will be integrated 
in the WHO’s UHC compendium of interventions, 
containing interventions across all of WHO’s program-
matic health areas. In addition, the WHO VP will work 
closely with representatives from other related WHO 
programmes, including ageing, primary care, diabetes 
and maternal and child health, to ensure relevant 
PECI are aligned and integrated within the care pack-
ages of these programmes.
To address many of the challenges facing the eye 
care sector, including those relating to changing 
demographics, inequities in access, and lack of inte-
gration—eye care needs to be an integral part of UHC. 
In summary, the development of the PECI described 
herein aims to move forward the agenda of eye care as 
part of UHC by providing countries with information 
on evidence- based eye care interventions, including 
resource requirements for their implementation, 
to facilitate the integration of eye care into national 
health services packages and policies. It is therefore 
the intention that the PECI will take an important 
step to strengthening eye care within health systems, 
enabling more people to benefit from eye care inter-
ventions.
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